Freshly IPO’d Tocagen tweaks brain cancer gene therapy test – FierceBiotech
FierceBiotech |
Freshly IPO'd Tocagen tweaks brain cancer gene therapy test
FierceBiotech The company got off an IPO in April worth $85 million toward its gene therapy tests, although it has lost value, going from $12.45 a share in mid-April to $9.23 yesterday, where it also closed down by more than 3%, and with a market cap of just over … Gene Therapy May Fight Brain Cancer's Return Tocagen's new gene therapy offers a flicker of hope for aggressive brain cancer Safety of gene therapy for brain tumours tested in early trial |
